Neuphoria Therapeutics Stock (NASDAQ:NEUP)

Ownership Financials Chart

Previous Close

$5.39

52W Range

$2.12 - $15.24

50D Avg

$5.18

200D Avg

$5.26

Market Cap

$9.09M

Avg Vol (3M)

$114.01K

Beta

0.26

Div Yield

-

NEUP Company Profile

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Dec 16, 2021

Website

NEUP Performance

NEUP Financial Summary

	Jun 24	Jun 23	Jun 22
Revenue	-	$20.00K	$260.00K
Operating Income	$-17.89B	$-31.97M	$-21.34M
Net Income	$-15.49B	$-31.85M	$-21.76M
EBITDA	$-17.89B	$-17.87M	$-11.51M
Basic EPS	$-0.01	$-0.02	$-0.02
Diluted EPS	$-0.01	$-0.02	$-0.02

Fiscal year ends in Jun 24 | Currency in USD